Mutated EGFR-IN-1

CAS No. 1421372-66-8

Mutated EGFR-IN-1( Osimertinib analog )

Catalog No. M23574 CAS No. 1421372-66-8

Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 43 In Stock
25MG 50 In Stock
50MG 57 In Stock
100MG 76 In Stock
200MG 110 In Stock
500MG 183 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Mutated EGFR-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
  • Description
    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Osimertinib analog
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR (L858R)|EGFR (T790M)|EGFR(Exon 19 deletion/T790M)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1421372-66-8
  • Formula Weight
    445.56
  • Molecular Formula
    C25H31N7O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 75 mg/mL (168.33 mM)
  • SMILES
    NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Patent WO 2013014448 A2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer .
molnova catalog
related products
  • CO-1686 hydrobromide

    A potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M.

  • Epimedin B

    Epimedin B has potential activity against osteoporosis by stimulating osteoblasts.

  • Sapitinib

    Sapitinib (AZD-8931, AZD8931) is a equipotent, reversible inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4. 3 and 4 nM (phosphorylation inhibition), respectively.